October 25, 2016
Novartis’s Q3 2016 net income $10,9B shorter than last year
Novartis’s Q3 2016 net income $10,9B shorter than last year
Pharmaceuticals, Biotechnology and Life Sciences
Novartis’s Q3 2016 net income $10,9B shorter than last year
Sun Pharmaceutical Industries, largest India-based generic pharmaceutical companies, has received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Novartis’ Gleevec.